These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35202726)

  • 1. Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
    Reinhardt LS; Morás AM; Henn JG; Arantes PR; Ferro MB; Braganhol E; de Souza PO; de Oliveira Merib J; Borges GR; Dalanhol CS; de Barros Dias MCH; Nugent M; Moura DJ
    Int J Pharm; 2022 Apr; 617():121584. PubMed ID: 35202726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
    Kadhim ZA; Sulaiman GM; Al-Shammari AM; Khan RA; Al Rugaie O; Mohammed HA
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
    Janjua TI; Cao Y; Ahmed-Cox A; Raza A; Moniruzzaman M; Akhter DT; Fletcher NL; Kavallaris M; Thurecht KJ; Popat A
    J Control Release; 2023 May; 357():161-174. PubMed ID: 36965857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
    Villamañan L; Martínez-Escardó L; Arús C; Yuste VJ; Candiota AP
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model.
    Michels LR; Fachel FNS; Schuh RS; Azambuja JH; de Souza PO; Gelsleichter NE; Lenz GS; Visioli F; Braganhol E; Teixeira HF
    J Control Release; 2023 Mar; 355():343-357. PubMed ID: 36731799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
    Gjika E; Pal-Ghosh S; Kirschner ME; Lin L; Sherman JH; Stepp MA; Keidar M
    Sci Rep; 2020 Oct; 10(1):16495. PubMed ID: 33020527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
    Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
    Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
    Zeng H; Yang Z; Xu N; Liu B; Fu Z; Lian C; Guo H
    Cell Death Dis; 2017 Jun; 8(6):e2885. PubMed ID: 28617438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

  • 19. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
    Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
    Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
    Banstola A; Duwa R; Emami F; Jeong JH; Yook S
    Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.